Anti-IL1RAP antibody
Antibodies targeting IL1RAP domain 3 inhibit the signaling of IL-1α, IL-1β, IL-33, IL-36α, IL-36β, and IL-36γ, addressing the comprehensive therapeutic needs for IL-1 family-related diseases by simultaneously targeting multiple cytokine pathways.
JP2026517839APending Publication Date: 2026-06-02OTSUKA PHARM CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- OTSUKA PHARM CO LTD
- Filing Date
- 2024-05-03
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517839000001_ABST
Abstract
The present invention relates to an antibody or antigen-binding fragment having binding specificity to interleukin-1 receptor accessory protein (IL1RAP). Furthermore, the present invention relates to a polynucleotide encoding the antibody, a vector containing the polynucleotide, and recombinant host cells containing the polynucleotide or the vector. Furthermore, the present invention relates to a method for producing the antibody or antigen-binding fragment. Furthermore, the present invention relates to a composition comprising the antibody or antigen-binding fragment, the polynucleotide, the vector, the host cell, and / or the host cell. Furthermore, the present invention relates to the antibody or antigen-binding fragment, the polynucleotide, the vector, the host cell, and / or the composition for use in the pharmacopoeia of a disease or disorder that is sensitive to treatment with inhibitors of IL-1α, IL-1β, IL-33, IL-36α, IL-36β, and / or IL-36γ signaling, and optionally, the disease or disorder is associated with cells expressing IL1RAP, and / or for use in the prevention and / or treatment and / or mitigation and / or detection and / or diagnosis thereof.
Need to check novelty before this filing date? Find Prior Art